文献速递细菌感染、耐药与抗菌药物

利福舒替尼三联疗法对比铋剂+克拉霉素三联疗法一线治疗幽门螺杆菌感染:EVEREST-HP 3期非劣效试验

Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial.
PubMed 文献 · Lancet Infect Dis · 2025-09-10

EVEREST-HP是在中国40家医院开展的3期、随机、三模拟、双盲、活性对照、非劣效试验,纳入700例初治幽门螺杆菌感染患者,比较利福舒替尼三联疗法(RTT)与铋剂+克拉霉素三联疗法(BCTT)14天方案的疗效与安全性。改良意向治疗人群中RTT根除率92·0%对BCTT 87·9%,绝对差4·2%(95%CI -0·3至8·8),达到非劣效;RTT治疗期间不良事件发生率更低(37%对53%)。

要点

  • RTT 14天方案根除率92·0%,非劣效于BCTT的87·9%。
  • 所有幽门螺杆菌临床分离株对利福舒替尼敏感。
  • RTT治疗期间不良事件37%,低于BCTT的53%。

核心结论

  • 在初治幽门螺杆菌感染患者中,利福舒替尼三联疗法根除率非劣效于铋剂+克拉霉素三联疗法,且治疗期间不良事件更少。
  • 利福舒替尼是首个专为幽门螺杆菌感染研发的新型抗菌药,RTT有望成为一线治疗选择。

研究设计与样本

  • 3期、多中心、随机、三模拟、双盲、活性对照、非劣效试验,采用适应性设计重新估计样本量,在中国40家研究医院开展。
  • 纳入18-65岁初治患者,[13C]尿素呼气试验阳性并经胃活检组织学确认,按1:1随机分入RTT(n=353)或BCTT(n=347),均每日两次、疗程14天。
  • 改良意向治疗人群为至少接受一剂研究药物的患者:RTT组351例、BCTT组346例,同时构成安全性集。

主要发现

  • 改良意向治疗分析中,RTT组根除率92·0%(95%CI 88·7至94·6;323/351),BCTT组87·9%(83·9至91·1;304/346),绝对差4·2%(95%CI -0·3至8·8)。
  • 579例(83%)患者幽门螺杆菌培养成功,其中克拉霉素耐药236/579(41%)、甲硝唑耐药395/579(68%)、左氧氟沙星耐药203/579(35%)、阿莫西林耐药47/579(8%)。
  • 所有幽门螺杆菌临床分离株均对利福舒替尼敏感。
  • RTT组治疗期间不良事件131/351(37%),BCTT组184/346(53%);RTT组发生率>5%的为腹泻24例(7%)、恶心22例(6%)、头晕21例(6%),BCTT组为味觉异常125例(36%)、恶心21例(6%)、腹泻19例(5%)。
  • 多数治疗期间不良事件为轻中度,未报告与研究药物相关的严重不良事件。

关键数值与推荐

  • 主要终点为非劣效检验,单侧α=0·025,非劣效界值-10%。
  • 主要终点为疗程结束后4-6周基于[13C]尿素呼气试验的根除率。
  • RTT方案:利福舒替尼400 mg口服胶囊、阿莫西林1 g口服胶囊、雷贝拉唑20 mg肠溶片,每日两次,14天。
  • BCTT方案:枸橼酸铋钾240 mg口服片、克拉霉素500 mg口服片、阿莫西林1 g口服胶囊、雷贝拉唑20 mg肠溶片,每日两次,14天。

临床怎么用

  • 对初治幽门螺杆菌感染,可考虑利福舒替尼三联疗法作为一线选择,其根除率非劣效且不良事件更少。
  • 在克拉霉素等耐药率较高的地区,利福舒替尼体外敏感结果支持其应对抗菌药物耐药的潜力。
  • 用药期间关注腹泻、恶心、头晕等不良事件,多数为轻中度。

局限性

  • 研究仅在中国40家医院开展,结论外推至其他地区人群需谨慎。
  • 随访至疗程结束后4-6周的[13C]尿素呼气试验,未报告更长期根除或复发数据。
  • 由TenNor Therapeutics资助,可能存在申办方相关偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rifasutenizol (TNP-2198) is a new molecular entity with a synergistic dual mechanism of action under clinical development for the treatment of Helicobacter pylori infection. We aimed to evaluate the efficacy and safety of a rifasutenizol-based triple therapy (RTT) versus bismuth plus clarithromycin-based triple therapy (BCTT) for the treatment of H pylori infection in treatment-naive patients. METHODS: EVEREST-HP was a phase 3, randomised, triple-dummy, double-blind, active-controlled, non-inferiority trial with adaptive design for sample size re-estimation conducted at 40 research hospitals in China. Treatment-naive patients aged 18-65 years, with a positive [13C]urea breath test ([13C]UBT), further confirmed by gastric biopsy and histological examination, were randomly assigned (1:1) to receive RTT (rifasutenizol 400 mg oral capsules, amoxicillin 1 g oral capsules, and rabeprazole 20 mg enteric-coated tables) or BCTT (bismuth potassium citrate 240 mg oral tablets, clarithromycin 500 mg oral tablets, amoxicillin 1 g oral capsules, and rabeprazole 20 mg enteric-coated tablets), all twice a day for 14 days. Randomisation was done centrally by a secure interactive web response system using block sizes of two or four and stratified by study site. RTT was compared against BCTT using a triple-dummy approach to ensure masking. The primary endpoint was H pylori eradication rate based on [13C]UBT 4-6 weeks after the end of treatment in the modified intention-to-treat population, which included all participants who received at least one dose of the study drugs. The eradication rates of RTT and BCTT were compared using a one-sided α value of 0·025 and a non-inferiority margin of -10%. Safety endpoints included investigator assessed treatment-emergent adverse events, the severity and relationship with study drugs, findings from physical examinations, vital signs, laboratory tests, and electrocardiogram. An interim analysis was conducted by an independent data monitoring committee after 50% (350) of patients completed the last [13C]UBT. The trial is registered with ClinicalTrials.gov, NCT05857163. FINDINGS: Between May 18, 2023, and Nov 10, 2023, 1267 patients were screened and 700 patients were randomly assigned to receive either RTT (n=353) or BCTT (n=347). 261 (37%) patients were men and 439 (63%) were women. 351 patients in the RTT group and 346 in the BCTT group took at least one dose of the study drugs and were included in the modified intention-to-treat group and the safety set. H pylori was successfully cultured from 579 (83%) of 697 patients. 236 (41%) of 579 patients had H pylori infection resistant to clarithromycin, 395 (68%) to metronidazole, 203 (35%) to levofloxacin, and 47 (8%) to amoxicillin. All H pylori clinical isolates were susceptible to rifasutenizol. In the modified intention-to-treat analysis, the H pylori eradication rate in the RTT group was non-inferior to that in the BCTT group (92·0% [95% CI 88·7 to 94·6; 323 of 351] vs 87·9% [83·9 to 91·1; 304 of 346]; absolute difference 4·2% [95% CI -0·3 to 8·8]). 131 (37%) of 351 patients in the RTT group and 184 (53%) of 346 in the BCTT group had treatment-emergent adverse events. Treatment-emergent adverse events occurring in more than 5% of patients in the RTT group were diarrhoea (in 24 [7%] patients), nausea (22 [6%]), and dizziness (21 [6%]), and in more than 5% of patients in the BCTT group were taste perversion (125 [36%]), nausea (21 [6%]), and diarrhoea (19 [5%]) Most of the treatment-emergent adverse events were mild or moderate in severity. No serious adverse event related to study drugs was reported. INTERPRETATION: As the first novel antimicrobial agent specifically developed for H pylori infection, rifasutenizol represents a promising addition to the existing options for tackling antimicrobial resistance, and RTT represents a promising first-line treatment option for H pylori infection. FUNDING: TenNor Therapeutics. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Song Z, Zhou L, Wang W, et al. Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial. Lancet Infect Dis. 2025. PMID: 40945526. doi:10.1016/S1473-3099(25)00438-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。